Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 176 participants.

Also called NCT07436182

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 176 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07436182
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07436182. Randomized; single masking; primary purpose basic science. Start 2026-03-01 (anticipated); primary completion 2026-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy
Acronym
MIRROR-DM
Condition
Mitochondria
Condition
Metformin
Intervention (Drug)
Imeglimin
Intervention (Drug)
Metformin 1000 mg Oral Tablet
Lead sponsor
Mansoura University (class: other)

Record details

Record id
cardio:ct-nct07436182
Content hash
aaa6a418c221dd8810d81c0a9ff07c7a94cbd0d4847a03e3df67fd969564c015